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                                                               ABSTRACT 
Background:  To describe characteristics and outcomes in women and men with heart failure 
(HF) and preserved ejection fraction (HFpEF). 
 
Methods & Results: Baseline characteristics (including biomarkers and quality-of-life) and 
outcomes (primary outcome: composite of first HF hospitalization or cardiovascular [CV] 
death) were compared in 4458 women and 4010 men enrolled in CHARM-Preserved (EF ≥
45%), I-Preserve and TOPCAT-Americas.  
Women were older and more often obese and hypertensive, but less likely to have coronary 
artery disease and atrial fibrillation. Women had more symptoms and signs of congestion, 
and worse quality-of-life. Despite this, the risk of the primary outcome was lower in women 
(HR 0.80; 95% CI 0.73-0.88), as was the risk of CV death (HR 0.70; 95% CI 0.62-0.80) but 
there was no difference in the rate for first hospitalization for HF (HR 0.92; 95% CI 0.82-
1.02). The lower risk of CV death in women, compared with men, was in part explained a by 
a substantially lower risk of sudden death (HR 0.53, 0.43-0.65; P<0.001). E/A ratio was 
lower in women (1.1 vs 1.2). 
 
Conclusions: There are significant differences between women and men with HFpEF. 
Despite worse symptoms, more congestion, and lower quality-of-life, women had similar 
rates of hospitalization and better survival than men. Their risk of sudden death was half that 
of men.   
Clinical Trial Registration: 
URL: https://www.clinicaltrials.gov. ATMOSPHERE: Unique identifier: NCT00853658. 
             PARADIGM-HF: Unique identifier: NCT01035255 
Word count: 213 
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Non-standard Abbreviations and Acronyms 
HFrEF – Heart failure with reduced ejection fraction 
HFpEF – Heart failure with preserved ejection fraction. 
CHARM – Candesartan in Heart failure: Assessment of Reduction in Mortality and 
morbidity. 
LVEF – Left ventricular ejection fraction. 
I-Preserve – Irbesartan in heart failure with Preserved ejection fraction.  
TOPCAT – Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist trial. 
BioLINCC – Blood Institute, Biologic Specimen and Data Repository Information 
Coordinating Center. 
NYHA – New York heart association.  
BNP – Brain natriuretic peptide. 
NT-proBNP – N-terminal pro brain natriuretic peptide. 
HR – Hazard ratio.  
eGFR – estimated glomerular filtration rate.  
IRR – Incidence rate ratio. 
KCCQ – Kansas city cardiomyopathy questionnaire. 
MLWHF – Minnesota living with heart failure.  
PARAGON-HF – Prospective Comparison of ARNI with ARB Global Outcomes in HF With 
Preserved Ejection Fraction. 
ARNI – Angiotensin receptor neprilysin inhibitor. 
ARB – Angiotensin receptor blocker.  
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INTRODUCTION 
Although much has been written about differences in the characteristics of, and outcomes in, 
men and women with heart failure (HF) with reduced ejection fraction (HFrEF), much less is 
known about these differences in heart failure with preserved ejection fraction (HFpEF).
1–3
  
In part, this reflects the few large trials in patients with the latter phenotype.  Moreover, the 
first major report on women with HFpEF was from Candesartan in Heart failure: Assessment 
of Reduction in Mortality and morbidity (CHARM)-Preserved trial which enrolled patients 
with a left ventricular ejection fraction (LVEF) >40%.
4
  Subsequent large trials have used 
45% as the threshold for the identification of HFpEF and, in retrospect, it is clear that many 
patients in CHARM-Preserved had characteristics more typical of HFrEF than HFpEF.
5
 The 
second of the large HFpEF trials to report, the Irbesartan in heart failure with Preserved 
ejection fraction trial (I-Preserve), described outcomes in women compared with men, but 
that analysis was limited by inclusion of only 1637 men.
6
 With the availability of a third large 
trial, the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist trial (TOPCAT), and using CHARM data on patients with a LVEF≥45%, it is 
now possible in an individual patient data meta-analysis, using a common definition of 
HFpEF, to conduct a more comprehensive analysis of outcomes according to sex (4458 
women and 4010 men) in all three trials.
5,7,8
 Although there was an echocardiographic sub-
study in (I-Preserve), cardiac structure and function were not analyzed by sex.
6
 TOPCAT also 
had an echocardiographic sub-study meaning that, along with I-Preserve, information on 
cardiac structure and function is available for 774 women and 625 men with HFpEF.
9
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METHODS 
The data that support the findings of this study for IPreserve and CHARM-preserved are 
available from the corresponding author on request. The data for TOPCAT is available upon 
request from a third party (BioLINCC).  
 
Study population 
For the present analyses, we pooled patients enrolled in CHARM-Preserved, I-Preserve and 
TOPCAT. The designs and results of these trials are published.
5,10,11
 Briefly, in CHARM-
Preserved 3023 HF patients in New York Heart Association (NYHA) class II to IV with a 
LVEF >40% were randomized to receive candesartan or placebo. I-Preserve compared 
irbesartan with placebo in 4128 patients aged ≥60 years in NYHA functional class II to IV, a 
LVEF ≥45% and echocardiographic, electrocardiographic or radiologic evidence supporting a 
diagnosis of HF. Patients in NYHA functional class II were required to have had a HF 
hospitalization within the previous 6 months. TOPCAT compared spironolactone with 
placebo in 3445 patients who aged ≥50 years in functional class II to IV with a LVEF ≥45%; 
patients were also required to have been hospitalized within the previous 12 months for HF or 
to have an elevated natriuretic peptide level within 60 days before randomization (i.e. Brain 
natriuretic peptide (BNP) ≥100 pg/ml or N-terminal pro Brain natriuretic peptide (NT-
proBNP ≥360 pg/ml)).  
For this analysis, we excluded 450 patients from CHARM-Preserved who had a LVEF<45% 
to ensure a consistent lower LVEF threshold across trials. Patients from TOPCAT who were 
randomized in Russia(N=1066) and Georgia (N=612) were also excluded because of doubts 
about diagnosis raised by the substantially lower event rates in this region, compared to those 
in the Americas, as well as doubts about treatment adherence.
12
 Accordingly, we have 
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analyzed 2573 patients enrolled in CHARM-preserved, 4128 patients from I-Preserve and 
1767 patients enrolled in TOPCAT-Americas. 
Each trial was approved by the ethics committee at participating centers and all patients 
provided written informed consent. 
The median duration of follow up was 41.3 months in the pooled cohort (36.6 months in 
CHARM-Preserved, 52.9 months in I-Preserve and 41.1 months in TOPCAT). 
 
Outcomes 
The primary outcome was a composite of cardiovascular (CV) death or HF hospitalization in 
CHARM-Preserved, all-cause death or CV hospitalization in I-Preserve, and a composite of 
CV death, HF hospitalization or aborted cardiac arrest in TOPCAT. In the present study, we 
used a composite of CV death or HF hospitalization as the primary outcome as this is now the 
most widely used endpoint in HF trials. We also analyzed each of the components of this 
composite, the two main modes of CV death (sudden death and death due to worsening HF), 
non-CV death and all-cause death. In addition, risk of other hospitalizations (CV, non-CV 
and all-cause) and fatal or non-fatal myocardial infarction and stroke were examined. Lastly, 
given the high burden of hospitalization in HFpEF, we examined recurrent as well as first 
admissions (for HF, all CV causes, non-CV causes and any cause). 
HF hospitalization and causes/modes of death were adjudicated by a central endpoint 
committee according to similar pre-specified criteria in each trial (the same committee 
adjudicated the events in CHARM-Preserved and TOPCAT). 
 
Statistical analyses  
Baseline characteristics are presented as means with standard deviations or medians with 
interquartile ranges for continuous variables and frequencies and percentages for categorical 
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variables. Baseline characteristics according to sex were compared using Student’s t-test or 
Mann-Whitney U test as appropriate for continuous variables, and chi-square test for 
categorical variables.  
Competing risk regression using the Fine-Grey method was employed to analyze outcomes 
(to account for the risk of multiple potential competing events). All outcomes are reported as 
number of events and sub-distribution hazard ratios (HRs) with 95% confidence intervals 
(CIs). Both the primary outcome and CV death were tested for the competing risk of non-CV 
death. First hospitalization for HF was tested for competing risk of all-cause death.  Sudden 
death was tested for the competing risk of non-sudden death and death due to worsening HF 
was tested for death not caused by worsening HF. Non-CV death was tested for competing 
risk of CV death. Fatal and nonfatal myocardial infarction (MI) and strokes were tested for 
competing risk of all cause death not due to MI or stroke.   HRs adjusted for trial, randomized 
treatment, region, age, heart rate, systolic blood pressure (SBP), body mass index (BMI), 
NYHA functional class, LVEF, estimated glomerular filtration rate(eGFR) and NT-proBNP 
(with missing indicator method used to handle missing eGFR and NT-proBNP values) have 
been reported (Model 1).
13
 We have also reported outcomes adjusted for  a second model 
which includes comorbidities in addition to variables incorporated in model 1. 
A sensitivity analysis for unobserved confounding (potentially not otherwise corrected by 
covariate adjustment) for the main outcomes by propensity score matching to balance 
available baseline covariates was also carried out. This analysis only included IPreserve and 
TOPCAT so that eGFR, which was missing in > 50% of patients in CHARM-preserved, 
could be used as one of the matching covariates. We matched 830 women with 830 men 
based on the propensity scores so derived.  
Recurrent hospitalizations were analyzed using negative binomial regression which is a 
counting method for the analysis of recurrent events and incidence risk ratios (IRRs) with 
10 
 
95% CIs are reported. IRRs adjusted for the two models as mentioned above are reported. 
Event rates per 1000 person-years are also reported, calculated by dividing the total number 
of events in each patient for each type of hospitalization by the total follow-up time for each 
patient.  
All analyses were performed using Stata version 15 (Stata Corp. College Station, Texas, 
USA). A two-sided p-value <0.05 was considered significant. 
 
Analysis of echocardiography subset 
Measures of left ventricular (LV) structure were indexed to body surface area (BSA) and 
diastolic dysfunction is described as recommended in current guidelines.
14
 Baseline 
characteristics of the patients in the echocardiography subset are reported in the 
supplementary tables. The outcomes of interest were further adjusted for in the 
echocardiography subgroup by adding E wave velocity, LV mass index and left atrial (LA) 
volume index to Model 1.  
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RESULTS  
There were 4010 men and 4558 women in our analysis, accounting for 47.4% and 52.6% of 
the cohort respectively.  
 
Baseline characteristics  
The baseline characteristics in men and women have been shown in Table 1. Women were at 
an average 2.5 years older than men, had higher SBP, heart rate and BMI. A greater 
proportion of women than men (48.7% vs. 41.2% men) were obese.
15
  
 
Comorbidities 
Apart from hypertension (86.6% women vs. 76.6% men), women were less likely to have a 
history of major comorbidities such as atrial fibrillation (30.6% vs. 33.9%), and coronary 
heart disease (49.1% vs. 62.9%). Electrocardiographically documented atrial fibrillation was 
also less common in women than men (16.9% vs. 20.4%). Among non-CV comorbidities, 
women had a similar prevalence of diabetes (30.7% vs. 32.0%) but a lower prevalence of 
chronic obstructive pulmonary disease/ asthma (11.2% vs. 13.8%). 
Women were also less likely to be current smokers (6.8% vs. 13.2%) and had lower intake of 
alcohol than men. 
 
Heart failure characteristics and investigations 
As shown in Table 1, women had been hospitalized for HF as often as men within the 6 
months before randomization. Women had more symptoms of HF than men, with a higher 
prevalence of orthopnea (28.9% vs. 21.0%) and paroxysmal nocturnal dyspnea (14.3% vs. 
12.0%; only recorded in I-Preserve and TOPCAT-Americas) and more evidence of 
congestion (peripheral edema and rales).  Women were considerably more likely to be in a 
12 
 
worse NYHA functional class (62.8% NYHA class III/IV vs. 51.3% in men) and had poorer 
health-related quality-of-life (QoL) i.e. lower (worse) median Kansas City Cardiomyopathy 
Questionnaire (KCCQ) scores (56.3 vs. 64.6 in men) or higher (worse) Minnesota Living 
with Heart Failure (MLWHF) scores (44.0 vs. 37.0). Each individual KCCQ domain score 
was also lower in women [Supplementary Figure 1] and each of the MLWHF domains and 
majority of the scores to questions in the MLWHF questionnaire were higher in women 
[Supplementary Figures 2 and 3].  
Women had a significantly higher LVEF (59.8% vs. 56.3%) than men and a lower median 
NT-proBNP (women 348pg/ml vs. men 484pg/ml), although the latter difference was 
confined to patients without atrial fibrillation.  
Mean eGFR was lower in women than men and a higher proportion of women had an eGFR 
<60 ml/min/1.73m
2
 (38.9% vs. 32.4% in men). There was no other difference in measures of 
blood chemistry. 
 
Background treatment 
The proportion treated with a diuretic was larger in women than in men (84.7% vs. 78.5%) 
[Table 1]. Women were less likely to receive digoxin (15.5% vs. 19.1%). Beta-blocker use 
was also slightly less in women (60.8% vs. 63.0%) whereas use of calcium channel blockers 
(CCBs) was more frequent (40.1% vs. 34.2%).  The differences between men and women in 
the proportions using statins, aspirin and anticoagulants were larger (all used less commonly 
in women). 
 
Echocardiographic measurements (I-Preserve and TOPCAT-Americas only) 
Women in the echocardiography subset were older, were more obese, and had fewer major 
comorbidities apart from hypertension similar to what was observed in the main cohort 
13 
 
[Table 2 and Supplementary Table 2]. As shown in Table 2, indexed LV volumes and LV 
mass were lower in women than in men. Indexed LA volume was increased above normal in 
both sexes but did not differ between men and women (even though men had greater LV 
volumes). Stroke volume was low in both sexes. While peak E wave velocity was similar in 
both sexes, women had a higher peak A wave velocity (83.7cm/s vs. 73.2cm/s). 
Consequently, E/A ratio was lower in women (1.1 vs. 1.2). Other measures of diastolic 
function, generally, did not differ notably between men and women.  
 
Outcomes 
Women had a significantly lower risk of the primary composite with an HR (model 1) of 0.80 
(95% CI 0.73–0.88), as shown in Table 3 & Figures 1 and 2.  
Looking at the components of this composite, the risk of first hospitalization for HF did not 
differ significantly between women and men (HR 0.92; 95% CI 0.82–1.02). 
By contrast, the risk of CV death (HR 0.70; 95% CI 0.62-0.80) was lower, as were each of 
the two major modes of CV death, that is sudden death and death due to worsening HF. The 
risk of sudden death in women was about half that in men (HR 0.53; 95% CI 0.43-0.65; 
P<0.001). 
The risk of non-CV death was also lower in women and, as a result, so was the risk of all-
cause death (HR 0.62; 95% CI 0.52–0.74 and 0.65; 95% CI 0.59–0.72, respectively). 
While women were less likely to have a fatal/non-fatal MI than men (HR 0.75; 95% CI 0.61-
0.94), the risk of stroke was similar (HR 0.87; 95% CI 0.70-1.07).  
The results were not altered in the subset of patients with echocardiographic data or in a 
sensitivity analysis using propensity score to match men and women [Supplementary Tables 
3 and 4 & Supplementary Figure 4].  
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Recurrent events 
During a median follow up of 1255 (1-2278) days, there were a total of 6610 hospitalizations 
for any cause in women and 6507 hospitalizations for any cause in men [Table 4]. Of these, 
1479 (22.4%) were due to HF in women and 1327 (20.4%) were due to HF in men. Among 
women, 7.4% had more than one hospitalization for HF and the same was true for 7.2% of 
men [Supplementary Table 1].  
The incidence risk ratio (IRR) for recurrent HF hospitalization for women compared with 
men was 0.87 (95% CI 0.77–1.00). The IRRs for CV hospitalization (0.84; 0.77–0.91), all-
cause hospitalization (0.85; 0.79–0.90) and non-CV hospitalizations (0.86; 0.79–0.93) were 
similar to those for HF hospitalization. 
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DISCUSSION 
Epidemiologic and registry studies show that women are as likely as men to suffer from 
HFpEF and this is what we also found in our pooled clinical trial cohort.
16,17
 Among the 8468 
individuals randomized, 4458 (53%) were women. There were notable differences between 
men and women: in our study women were older than men, more often had a history of 
hypertension and were more often obese than men (but did not have a greater prevalence of 
diabetes). Most comorbid conditions were less common in women than in men, with a 
particularly large difference in prevalence of CAD. These differences are consistent with 
prior studies.
18,19
 More novel were our findings related to the impact of HF on women, 
compared with men. Women had worse NYHA functional class, worse symptoms and more 
signs of congestion (and more often received diuretics) than men. These physician 
reported/recorded indicators of worse heart failure status in women were supported by patient 
reported outcomes. Specifically, health-related QoL (as measured by KCCQ in TOPCAT-
Americas and MLWHF in I-Preserve and CHARM-Preserved) was worse in women than 
men an all domains of QoL were worse in women compared to men. Interestingly, this worse 
clinical picture was apparent despite a lower median NT proBNP and higher LVEF (and 
smaller indexed LV volumes and mass) in women, compared with men. How one interprets 
this dissociation between symptoms/signs/QoL and physiological measures of cardiac 
function in women compared with men is uncertain. Is it that women experience worse 
symptoms of HF for any given level of cardiac dysfunction? Or is it that their symptoms and 
signs of congestion reflect an inadequate natriuretic peptide response in women? 
Alternatively, are women relatively undertreated with diuretics? While the proportion of 
patients treated with a loop diuretic was similar in men and women, more women were 
treated with a thiazide diuretic. Arguably, diuretics were underutilized in view of the greater 
congestion in women. Renal function may be relevant here too as it was worse in women. 
16 
 
With respect to outcomes, women were at a lower risk of the primary composite endpoint 
than men, due to a substantially lower risk of CV death (and not HF hospitalization). This 
was also true for the two main modes of CV death, non-CV death and, therefore, death 
overall. However, the most striking difference between women and men was in the risk of 
sudden death, which occurred almost twice as frequently in men as in women. This may be 
explained the lower prevalence of CAD in women and because sudden death is linked to 
CAD.
20
 However, this may not be the whole answer as when just individuals with CAD were 
examined, women still appeared less likely than men to die suddenly. 
By contrast, the proportion of patients experiencing one or more hospitalization for HF did 
not differ between women and men. When HF admissions were examined (using both first 
and repeat hospitalizations), taking account of the competing risk of death, women still had a 
similar rate of events to men in the unadjusted analysis.  
Overall, therefore, the impact of HFpEF seems to differ in men and women with women 
having worse symptoms and QoL, similar rates of hospital admission but lower rates of death 
than men. This raises the possibility that the goals of management of HFpEF in men and 
women might have a different emphasis, with women needing relatively more attention paid 
to well-being than men. This difference in impact may also extend to and have implications 
on pharmacological therapy in HFpEF. An analysis of TOPCAT showed that while there was 
no sex based difference in the risk of the primary composite outcome according to 
randomized treatment, women who received spironolactone had a lower risk of all-cause and 
cardiovascular death while no such benefit was seen in men.
21
 Similarly, in the recent 
Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved 
Ejection Fraction (PARAGON-HF) trial, only women receiving sacubitril/valsartan had a 
statistically significant reduction in risk of the primary outcome while there was no risk 
reduction observed in men.
22
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Finally, it is also of interest to compare these findings in HFpEF with a recent similar 
analysis in HFrEF.
23
 Both men and women with HFpEF were quite different than people with 
HFrEF e.g. people with HFpEF were 6 years older on average and had a 12mmHg higher 
average systolic blood pressure.
23
 Obesity was more common in HFpEF than HFrEF and this 
difference was more marked in women (48.7% in HFpEF vs. 33.4% in HFrEF) than men 
(41.2% vs. 29.2%, respectively). Women had more symptoms/signs of congestion in both 
HFpEF and HFrEF. QoL was worse in HFpEF than in HFrEF, overall, but worse in women 
than men in both HF phenotypes. A notable distinction between HFpEF and HFrEF, with 
respect to sex differences, was the similar rate of hospital admission in women and men with 
HFpEF (contrasting with the lower risk in women, compared to men, with HFrEF). The risk 
of sudden death was less in women with HFrEF than in men with HFrEF, although the 
between-sex difference was smaller than in HFpEF.
23
 
 
Strengths and limitations 
We studied patients enrolled in clinical trials who had to fulfil specific inclusion and 
exclusion criteria and they may not be representative of HFpEF patients more generally. 
However, because these patients were enrolled in trials, they were well characterized at 
baseline and had systematic and complete follow-up, with adjudication of clinical outcomes. 
Not all data were available in all three trials.  
In conclusion, we found significant sex-based differences in patients with HFpEF. Women 
were older and more likely than men to be hypertensive and obese (but less likely to have 
CHD). Despite worse symptoms, more evidence of congestion, and lower QoL, women had 
similar rates of hospitalization to men and a better survival. Their risk of sudden death was 
half that of men.  
18 
 
What is new 
 Women with HFpEF live longer when compared to men with HFpEF but have a 
poorer quality of life and a greater symptom burden.   
 Overall mortality in both genders with HFpEF is lesser than that observed in HFrEF. 
Fewer men with HFpEF had hospitalizations for heart failure when compared with 
HFrEF but no such difference was observed in women with HFpEF and HFrEF. 
 
Clinical implications 
 While no pharmacological therapy to date has been approved for the treatment of 
HFpEF patients overall, recent evidence suggests there may be benefit from certain 
agents in women with this heart failure phenotype.  
 The former findings, plus the striking contrasts reported here, between the 
characteristics and outcomes of women, compared with men with HFpEF, argue for 
intensified efforts to understand and explain these sex-related differences. We believe 
this should be a clinical priority given the worse quality of life and symptoms 
experienced by women with HFpEF and the fact that this is the major type of heart 
failure afflicting women.   
  
Sources of funding 
None 
 
 
19 
 
REFERENCES 
1.  Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, 
Young JB, Goldman S, Peberdy MA, Lindenfeld J. Gender Differences in Advanced 
Heart Failure: Insights from the BEST Study. J Am Coll Cardiol. 2003;42:2128–2134.  
2.  Rathore SS, Wang Y, Krumholz HM. Sex-Based Differences in the Effect of Digoxin 
for the Treatment of Heart Failure. N Engl J Med. 2002;347:1403–1411.  
3.  Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the 
prognosis of congestive heart failure results from the Cardiac Insufficiency Bisoprolol 
Study (CIBIS II). Circulation. 2001;103:375–380.  
4.  O’Meara E, Clayton T, McEntegart MB, McMurray JJ V, Piña IL, Granger CB, 
Östergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer 
MA. Sex differences in clinical characteristics and prognosis in a broad spectrum of 
patients with heart failure - Results of the Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity (CHARM) program. Circulation. 
2007;115:3111–3120.  
5.  Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, 
Olofsson B, Östergren J. Effects of candesartan in patients with chronic heart failure 
and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet. 
2003;362:777–781.  
6.  Lam CSP, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie 
RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical 
characteristics and outcomes in elderly patients with heart failure and preserved 
ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (I-
PRESERVE) trial. Circ Hear Fail. 2012;5:571–578.  
7.  Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson 
20 
 
S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. 
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 
2008;359:2456–67.  
8.  Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai 
AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, 
O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, 
Yang S, McKinlay SM. Spironolactone for Heart Failure with Preserved Ejection 
Fraction. N Engl J Med. 2014;370:1383–1392.  
9.  Shah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, Sopko G, Li G, 
Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and 
function in heart failure with preserved ejection fraction: Baseline findings from the 
echocardiographic study of the treatment of preserved cardiac function heart failure 
with an aldosterone antagonist trial. Circ Hear Fail. 2014;7:104–115.  
10.  Carson P, Massie BM, Mckelvie R, Mcmurray J, Komajda M, Zile M, Ptaszynska A, 
Frangin G. The Irbesartan in Heart Failure with Preserved Systolic Function (I-
PRESERVE) trial: Rationale and design. J Card Fail. 2005;11:576–585.  
11.  Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, 
Fleg JL, Gordeev I, McKinlay S, O’Meara E, Shaburishvili T, Pitt B, Pfeffer MA. 
Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure 
with an Aldosterone Antagonist Trial: A randomized, controlled study of 
spironolactone in patients with symptomatic heart failure and preserved ejection 
fraction. Am Heart J. 2011;162:966-972.e10.  
12.  Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, 
Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau J-LLJ-L, 
Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, 
21 
 
Pitt B, O’Meara E, Rouleau J-LLJ-L, Probstfield JL, Shaburishvili T, Shah SJ, 
Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and 
outcomes in the treatment of preserved cardiac function heart failure with an 
aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.  
13.  Huberman M, Langholz B. Application of the Missing-Indicator Method in Matched 
Case-Control Studies with Incomplete Data. Am J Epidemiol [Internet]. 
1999;150:1340–1345. Available from: https://academic.oup.com/aje/article-
lookup/doi/10.1093/oxfordjournals.aje.a009966 
14.  Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, 
Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Alexandru 
Popescu B, Waggoner AD. Recommendations for the Evaluation of Left Ventricular 
Diastolic Function by Echocardiography: An Update from the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear 
J – Cardiovasc Imaging. 2016;17:1321–1360.  
15.  The World Health Orginisation. WHO | Mean Body Mass Index (BMI). WHO 
[Internet]. 2017 [cited 2019 Sep 28];Available from: 
https://www.who.int/gho/ncd/risk_factors/bmi_text/en/ 
16.  Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, Ong HY, Jaufeerally 
F, Ng TP, Cameron VA, Poppe K, Lund M, Devlin G, Troughton R, Richards AM, 
Doughty RN. Mortality associated with heart failure with preserved vs. reduced 
ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 
2018;39:1770–1780.  
17.  Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, 
Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new 
onset heart failure with preserved vs. reduced ejection fraction in a community-based 
22 
 
cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34:1424–1431.  
18.  Lloyd-Jones DM, Allen NB, Greenland P, Ayers C, Kuller LH, Eaton CB, Klein L, 
LaMonte M, Pandey A, Berry JD, Gottdiener JS, Omar W. Sex and Race Differences 
in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure 
With Reduced Ejection Fraction. Circulation. 2018;137:1814–1823.  
19.  Gori M, Lam CSP, Gupta DK, Santos ABS, Cheng S, Shah AM, Claggett B, Zile MR, 
Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, 
McMurray JJ V., Solomon SD. Sex-specific cardiovascular structure and function in 
heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;16:535–542.  
20.  Yarnoz MJ, Curtis AB. More Reasons Why Men and Women Are Not the Same 
(Gender Differences in Electrophysiology and Arrhythmias). Am J Cardiol. 
2008;101:1291–1296.  
21.  Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex Differences in Outcomes and 
Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A 
Secondary Analysis of TOPCAT Trial. JACC Hear Fail. 2019;7:228–238.  
22.  Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, 
Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, 
Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, 
Cleland J, Düngen H-D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, 
Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP. 
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N 
Engl J Med [Internet]. 2019;NEJMoa1908655. DOI: 10.1056/NEJMoa1908655 
23.  Dewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai 
AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, 
Swedberg K, Zile MR, McMurray JJV. Differential Impact of Heart Failure With 
23 
 
Reduced Ejection Fraction on Men and Women. J Am Coll Cardiol. 2019;73:29–40.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
TABLE LEGENDS 
 
Table 1: Characteristics of women and men with HFpEF. 
Table 2: Echocardiographic parameters in women and men with HFpEF. (I-Preserve and 
TOPCAT). 
Table 3: Clinical outcomes in women and men with HFpEF. 
Table 4: Analysis of repeat hospitalizations in women and men with HFpEF (negative 
binomial model). 
 
FIGURE LEGENDS 
 
Figure 1: Central Figure - Sex based differences in Heart Failure with preserved Ejection 
Fraction. 
Figure 2: Clinical outcomes in women and men with HFpEF: a) Primary composite outcome 
b) Hospitalization for Heart Failure c) Cardiovascular Death d) All-cause Death e) Sudden 
Death f) Death due to worsening HF i) Fatal/Non-fatal Myocardial Infarction j) Fatal/Non-
fatal Stroke. All figures are cumulative incidence plots except all-cause death (Kaplan-
Meier). 
 
 
 
 
 
 
25 
 
Table 1: Patient Characteristics 
 Women 
4458 (52.6) 
Men 
4010 (47.4) 
p-value 
Baseline Characteristics 
Age–mean ± SD 71.4 ± 8.7 68.9 ± 9.6 <0.001 
Age Groups–no.(%) 
 
 <0.001 
    ≤40 years 9 (0.2) 24 (0.6) 
 
    41-55 years 177 (4.0) 312 (7.8) 
 
    56–70 years 1800 (40.4) 1852 (46.2) 
 
    >70 years 2472 (55.5) 1822 (45.4) 
 
Region-no. (%) 
 
 <0.001 
    North America 1332 (29.9) 1483 (37.0) 
 
    Latin America 679 (15.2) 327 (8.2) 
 
    Western Europe & other 1351 (30.3) 1361 (33.9) 
 
    Central Europe 1019 (23.9) 735 (18.3) 
 
    Asia-Pacific 77 (1.7) 104 (2.6) 
 
Race–no. (%) 
 
 <0.001 
    White 3925 (88.0) 3671 (91.5) 
 
    Black 327 (7.3) 165 (4.1) 
 
    Asian 48 (1.1) 70 (1.7) 
 
    Other 158 (3.5) 104 (2.6) 
 
SBP (mmHg)–mean ± SD 136.0 ± 16.4 133.0 ± 17.1 <0.001 
DBP (mmHg)–mean ± SD 77.0 ± 10.4 77.0 ± 10.7 0.27 
HR (bpm)–mean ± SD 72.0 ± 11.2 70.0 ± 11.6 <0.001 
BMI (kg/m
2
)–median (Q1, Q3) 29.8 (26.1,34.4) 28.7 (25.9,32.7) <0.001 
Weight Category–no. (%) 
 
 <0.001 
    Underweight 31 (0.7) 18 (0.5) 
 
    Normal 753 (17.0) 687 (17.2) 
 
    Overweight 1493 (33.6) 1643 (41.2) 
 
    Obese 2165 (48.7) 1642 (41.2) 
 
Comorbidities-no. (%)    
Cardiovascular    
   Atrial fibrillation(history) 1362 (30.6) 1359 (33.9) <0.001 
   Hypertension 3859 (86.6) 3071 (76.6) <0.001 
   Coronary heart disease 2191 (49.1) 2522 (62.9) <0.001 
    Myocardial infarction 879 (19.7) 1505 (37.5) <0.001 
    Angina 1834 (41.1) 1950 (48.7) <0.001 
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    PCI or CABG 681 (15.3) 1263 (31.5) <0.001 
   Stroke or TIA 393 (8.8) 386 (9.6) 0.20 
Other Systems    
   Type II Diabetes 1369 (30.7) 1284 (32.0) 0.1887 
   COPD/Asthma 498 (11.2) 553 (13.8) 0.0003 
   Peripheral arterial disease
*
 733 (21.7) 567 (22.5) 0.481 
   Anemia
*
 553 (16.4) 628 (24.9) <0.001 
   Any alcohol intake
*
  291 (8.6) 617 (24.5) <0.001 
Current smoker
†
 134 (6.8) 313 (13.2) <0.001 
Heart Failure Characteristics, Investigations and Treatment 
HF hospitalization within past 6 months–no. (%) 1883 (42.2) 1625 (40.5) 0.11 
NYHA III/IV–no. (%) 2801 (62.8) 2059 (51.3) <0.001 
Quality of Life scores    
Minnesota LWHF–median (Q1, Q3) 44.0 (29.0,61.0) 37.0 (22.0,54.0) <0.001 
KCCQ Clinical Summary Score–median (Q1, Q3) 56.3 (39.1,72.9) 64.6 (45.8,82.3) <0.001 
Markers of Congestion–no (%) 
 
 
 
Dyspnea on effort
†
 1922 (97.7) 2312 (97.5) 0.61 
Orthopnea
†
 565 (28.9) 496 (21.0) <0.001 
PND
†
  279 (14.3) 282 (12.0) 0.02 
Peripheral edema 2371 (53.2) 1920 (47.9) <0.001 
JVD 410 (9.2) 428 (10.7) 0.02 
Rales 1033 (23.2) 830 (20.7) 0.008 
ECG–no. (%) 
 
 
 
Atrial fibrillation 752 (16.9) 816 (20.4) <0.001 
LVH 1043 (23.5) 760 (19.0) <0.001 
Echocardiography and other Investigations    
LVEF (%)-mean ± SD 59.8 ± 9.0 56.3 ± 8.3 <0.001 
CXR demonstrating pleural effusion or pulmonary. 
Congestion 
1057 (23.7) 611 (15.2) <0.001 
NT-proBNP(pg/ml)–median (Q1, Q3)
 *‡
           
348 
(133, 967) 
484 
(177, 1159) 
<0.001 
    No Atrial fibrillation on ECG
*
 (1934/2800) 
261 
(115, 619) 
340 
(138, 796) 
0.001 
    Atrial fibrillation on ECG* (574/569) 
1349 
(816, 2155) 
1231 
(733, 2015) 
0.20 
Sodium(mmol/L)–mean ± SD 139.8 ± 3.1 139.7 ± 3.0 0.05 
Potassium(mmol/L)-mean ± SD 4.36 ± 0.5 4.37 ± 0.46 0.21 
eGFR(ml/min/1.73m
2
)-mean ± SD
§  
68.8 ± 23.2 72.4 ± 23.0 <0.001 
eGFR <60 ml/min/m
2
–no. (%) 1454 (38.9) 972 (32.4) <0.001 
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Drugs and Interventions–no. (%)    
Diuretic 3772 (84.7) 3143 (78.5) <0.001 
    Loop diuretics 2675 (60.1) 2449 (61.1) 0.32 
    Thiazide diuretics 1417 (31.8) 942 (23.5) <0.001 
Digoxin 688 (15.5) 764 (19.1) <0.001 
Beta- blocker 2709 (60.8) 2523 (63.0) 0.04 
Calcium Channel Blocker 1784 (40.1) 1372 (34.2) <0.001 
Antiarrhythmics 380 (8.5) 382 (9.5) 0.11 
Antiplatelets 2482 (55.7) 2577 (64.3) <0.001 
Anticoagulants 977 (21.9) 1078 (26.9) <0.001 
  History of atrial fibrillation(n=1362/1359) 819 (60.1) 870 (64.0) 0.04 
Statins 1628 (36.6) 1902 (47.5) <0.001 
Pacemaker 319 (7.2) 363 (9.1) 0.001 
ICD 29 (0.7) 42 (1.0) 0.045 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), body mass index (BMI), inter quartile range 
(IQR), chronic obstructive pulmonary disease (COPD). 
COPD/Asthma in CHARM derived from patients using bronchodilators at baseline. 
New York heart association (NYHA), living with heart failure (LWHF), Kansas City cardiomyopathy questionnaire (KCCQ), 
jugular venous distension (JVD), left ventricular hypertrophy (LVH), left ventricular ejection fraction (LVEF), chest x-ray 
(CXR), N terminal -pro brain natriuretic peptide (NT-proBNP) – only available in I-Preserve and TOPCAT, estimated 
glomerular filtration rate (eGFR), angiotensin converting enzyme inhibitor (ACEI), implantable cardioverter defibrillator 
(ICD). 
Outlined box encloses values not available for the complete dataset. 
*
Only I-Preserve and TOPCAT (2522 men, 3373 women). 
  
†
Only CHARM-preserved and TOPCAT (2373 men, 1967 women). 
‡
Missing – 2057 
§
Missing - 1732 
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Table 2: Echocardiographic parameters in women and men with HFpEF. (I-Preserve and TOPCAT). 
 
Women 
774 (55.3) 
Men 
625 (44.7) 
p-value 
Age-years 71.8 ± 8.3 71.2 ± 8.7 0.1673 
LV Structure 
 
 
 
End-diastolic diameter(cm) 4.7 ± 0.6 5.0 ± 0.6 <0.001 
    End-diastolic diameter index(cm/m
2
) 2.5 ± 0.4 2.4 ± 0.4 <0.001 
End-diastolic volume(ml)  82.3 ± 28.6 110.3 ± 36.1 <0.001 
    End-diastolic volume index(ml/m
2
) 43.6 ± 14.6 52.2 ± 16.8 <0.001 
End-systolic diameter(cm) 3.1 ± 0.6 3.5 ± 0.6 <0.001 
    End-systolic diameter index(cm/m
2
) 1.7 ± 0.3 1.7 ± 0.3 0.59 
End-systolic volume(ml) 30.6 ± 14.5 44.6 ± 20.0 <0.001 
    End-systolic volume index(ml/m
2
) 16.2 ± 7.7 21.2 ± 9.7 <0.001 
Interventricular septum thickness(cm) 1.0 ± 0.2 1.2 ± 0.2 <0.001 
LV mass(gm) 191.5 ± 58.7 241.5 ± 65.6 <0.001 
    LV mass index(gm/m
2
) 101.7 ± 29.4 113.7 ± 28.9 <0.001 
Relative wall thickness(cm) 0.4 ± 0.1 0.5 ± 0.1 0.02 
LV Systolic Properties 
 
 
 
Ejection fraction (%) 61.8 ± 8.5 58.2 ± 7.9 <0.001 
Stroke volume(ml) 51.7 ± 18.1 65.6 ± 22.0 <0.001 
LV Diastolic properties 
 
 
 
Diastolic dysfunction*-no. (%)   0.65 
    Grade I 202 (6.1) 152 (24.3)  
    Grade II 32 (4.1) 20 (3.2)  
    Grade III 62 (8.0) 50 (8.0)  
    Undetermined 278 (61.8) 403 (64.5)  
Peak E wave velocity(cm/s) 81.1 ± 28.6 78.8 ± 28.0 0.18 
E/E' lateral ratio 11.3 ± 5.6 10.3 ± 5.0 0.01 
E/E' septal ratio 14.3 ± 6.6 14.1 ± 6.8 0.75 
E/E' average ratio 12.1 ± 5.4 11.6 ± 5.1 0.20 
Peak A wave velocity(cm/s) 83.7 ± 26.6 73.2 ± 23.9 <0.001 
E/A ratio 1.1 ± 0.7 1.2 ± 0.8 0.005 
Lateral early diastolic myocardial velocity(cm/s) 
 
8.6 ± 3.4 9.2 ± 3.5 0.01 
Septal early diastolic myocardial velocity(cm/s) 6.8 ± 2.9 6.9 ± 2.7 0.71 
Mitral deceleration time(msec) 212.7 ± 73.8 203.9 ± 65.6 0.02 
Left atrial volume(ml) 69.0 ± 30.1 77.3 ± 35.6 <0.001 
Left atrial volume index(ml/m
2
) 37.1 ± 16.8 36.9 ± 17.9 0.85 
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All values expressed as mean ± standard deviation except where indicated. 
*627 missing 
30 
 
Table 3: Clinical outcomes in men and women with HFpEF 
 Women 
4458 (52.6) 
Men 
4010 (47.4) 
Adjusted HR 
(Model 1) 
p-value 
Adjusted HR 
 (Model 2) 
p-value Total patients with events 
Primary composite 
outcome 
1087 1069 
0.80 (0.73–0.88) 
<0.001 
0.84 (0.76–0.92) 
<0.001 
     
Hospitalization     
 Heart Failure 787 703 
0.92 (0.82–1.02) 
0.123 
0.95 (0.85–1.06) 
0.385 
     
 Cardiovascular
 
1690 1682 
0.86 (0.80–0.92) 
<0.001 
0.90 (0.83–0.96) 
0.004 
     
 Non-cardiovascular 
 
1622 1525 
0.90 (0.84–0.97) 
0.008 
0.92 (0.85–0.99) 
0.032 
     
 All-cause
 
2517 2359 
0.91 (0.85–0.96) 
0.001 
0.94 (0.88–1.00) 
0.040 
     
Death     
Cardiovascular 533 583 
0.70 (0.62–0.80) 
<0.001 
0.72 (0.63–0.82) 
<0.001 
     
Sudden death 161 243 
0.53 (0.43– 0.65) 
<0.001 
0.53 (0.43–0.66) 
<0.001 
     
Death due to worsening 
HF 
129 139 
0.69 (0.54–0.89) 
0.005 
0.72 (0.55–0.93) 
0.012 
     
Non-cardiovascular 
 
261 301 
0.62 (0.52–0.74) 
<0.001 
0.63 (0.53–0.75) 
<0.001 
     
All-cause (HR) 794 884 
0.65 (0.59–0.72) 
<0.001 
0.67 (0.60–0.74) 
<0.001 
     
Others     
Fatal/Non-fatal MI 154 193 
0.75 (0.61–0.94) 
0.012 
0.80 (0.64–1.00) 
0.050 
     
Fatal/Non-fatal stroke 193 179 
0.87 (0.70–1.07) 
0.191 
0.88 (0.71–1.09) 
0.242 
     
Hazard Ratios are reported with 95% confidence intervals (CI) within () 
All outcomes have been adjusted for trial, randomized treatment and region at baseline. 
Adjustment Model 1– age, HR, SBP, DBP, BMI, NYHA classes III/IV, LVEF, eGFR, NT-proBNP.  
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Adjustment Model 2– age, HR, SBP, DBP, BMI, NYHA classes III/IV, LVEF, eGFR, NT-proBNP, H/o atrial fibrillation, H/o coronary heart 
disease, H/o hypertension, H/o stroke, H/o diabetes 
All outcomes were tested for competing risks of all-cause and non-cardiovascular death.  Sudden death was tested for competing risk 
of all non-sudden deaths and death due to worsening HF for all deaths not due to worsening HF. Non-CV death was tested for 
competing risk of CV death. 
Missing indicator method was used to handle missing eGFR and NT-proBNP values were imputed for missing values. 
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Table 4: Recurrent Admissions in men and women with HFpEF. 
 Women 
4458 (52.6) 
Men 
4010 (47.4) 
Women 
4458 (52.6) 
Men 
4010 (47.4) 
Adjusted IRR 
(Model 1) 
Adjusted IRR 
(Model 2) 
Total events Admissions per 100 patient years (95%CI) 
HF hospitalization 1479 1327 9.14 (8.68–9.62) 9.91 (9.39–10.46) 
0.87 (0.77–1.00) 
0.045 
0.87 (0.77–0.99) 
0.122 
       
CV hospitalization 3560 3590 22.0 (21.29–22.73) 26.81 (25.95–27.70) 
0.84 (0.77–0.91) 
<0.001 
0.87 (0.80–0.94) 
<0.000 
       
Non-CV hospitalization
 
3054 2919 18.87 (18.21–19.55) 21.80 (21.02–22.60) 
0.86 (0.79–0.93) 
<0.001 
0.88 (0.81–0.95) 
0.002 
        
All-cause hospitalization 6610 6507 40.84 (39.87–41.84) 48.59 (47.43–49.79) 
0.85 (0.79–0.90) 
<0.001 
0.87 (0.82–0.93) 
<0.001 
       
IRR denotes incident rate ratios with 95% confidence intervals (CI) within (). 
All outcomes adjusted for trial, randomized treatment and region at baseline. 
Adjustment Model 1 – age, HR, SBP, DBP, BMI, NYHA classes III/IV, LVEF, eGFR, NT-proBNP. 
Adjustment Model 2– age, HR, SBP, DBP, BMI, NYHA classes III/IV, LVEF, eGFR, NT-proBNP, H/o atrial fibrillation H/o coronary heart disease, H/o hypertension, H/o stroke, H/o diabetes. 
Missing indicator method used to handle missing eGFR and NT-proBNP. 
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Figure 1: Central Figure 
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Figure 2: Clinical outcomes: a) Primary composite outcome b) Hospitalization for heart failure c) 
Cardiovascular death d) All-cause death e) Sudden death f) Death due to worsening HF i) Fatal/non-fatal 
myocardial infarction j) Fatal/non-fatal stroke. All figures are cumulative incidence plots except all-cause 
death (Kaplan-Meier). 
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       APPENDIX 
 
TABLE LEGEND 
 
Supplementary Table 1: Number of hospital admissions women and men with heart failure and 
preserved ejection fraction. 
Supplementary Table 2: Characteristics of women and men with heart failure and preserved 
ejection fraction in the echocardiography sub-study. 
Supplementary Table 3: Clinical outcomes in women and men with heart failure and preserved 
ejection fraction in the echocardiography sub-study. 
Supplementary Table 4: Clinical outcomes in women and men with heart failure and preserved 
ejection fraction before and after matching by propensity score. 
FIGURE LEGEND 
 
Supplementary Figure 1: Kansas City Cardiomyopathy Scores. Y axis represents score out of a 
possible 100 (with lower score representing worse quality of life). Bars show median score for 
each domain/summary score (except mean for symptom severity). 
Supplementary Figure 2: Minnesota Living with Heart Failure Scores. Y axis represents score 
out of a possible 100 (with higher score representing worse quality of life). Bars show mean 
score for each domain/summary score (except median for physical dimension). 
Supplementary Figure 3: Responses to individual questions in the Minnesota Living with 
Heart Failure questionnaire. Y axis represents response to questions (0 – 5) and bars show mean 
response to each question. 
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Supplementary Figure 4: Standardized differences of covariates between men and women 
before and after propensity score matching.  
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Supplementary Table 1: Number of hospital admissions – no. (%) 
 
Women 
4458 (52.6) 
Men 
4010 (47.4) 
Heart failure 
0 3657 (82.0) 3302 (82.3) 
1 469 (10.5) 419 (10.5) 
≥2 332 (7.4) 289 (7.2) 
Cardiovascular 
0 2768 (62.1) 2328 (58.1) 
1 863 (19.4) 849 (21.2) 
≥2 827 (18.5) 833 (20.7) 
Non-cardiovascular  
0 2836 (63.6)  2485 (62.0) 
1 909 (20.4) 854 (21.3) 
≥2 713 (16.0) 671 (16.7) 
All-cause hospitalizations  
0 1941 (43.5) 1651 (41.2) 
1 1054 (23.6) 907 (22.6) 
≥2 1463 (32.9) 1452 (36.2) 
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Supplementary Table 2: Patient Characteristics (Echo substudy) 
 Women 
774 (55.3) 
Men 
625 (44.7) 
p-value 
Baseline Characteristics 
Age – mean (SD) 71.8 (8.3) 71.2 (8.7) 0.17 
Age Groups – no. (%)   0.18 
41 – 55 years 22 (2.8) 20 (3.2) 
 
56 – 70 years 309 (39.9) 278 (44.5) 
 
>70 years 443 (57.2) 327 (52.3) 
 
Race – no. (%)   0.03 
    White 648 (83.7) 554 (88.6) 
 
    Black 93 (12.0) 46 (7.4) 
 
    Asian 2 (0.3) 2 (0.3) 
 
    Other 31 (4.0) 23 (3.7) 
 
SBP (mmHg) – mean (SD) 133.0 (16.3) 130.6 (15.2) 0.003 
DBP (mmHg) – mean (SD) 75.8 (10.4) 74.3 (11.0) 0.01 
HR (bpm) – mean (SD) 70.0 (11.0) 68.9 (11.1) 0.07 
BMI (kg/m
2
) – median (Q1, Q3) 
30.9 (26.8, 35.4) 
 
30.4 (26.8, 34.7) 
 
0.31 
Weight Category – no. (%)   0.80 
    Underweight 4 (0.5) 2 (0.3) 
 
    Normal 102 (13.2) 85 (13.6) 
 
    Overweight 241 (21.1) 206 (33.0) 
 
    Obese 422 (54.5) 330 (52.8) 
 
Comorbidities -no. (%)    
Atrial fibrillation (Hx) 228(29.5) 245(39.3) 0.0001 
Hypertension 725(93.7) 553(88.6) 0.0008 
Coronary heart disease    
    Myocardial infarction 116(15.0) 170(27.2) <0.001 
    Angina 238(30.7) 235(37.7) 0.0066 
    PCI or CABG 115(14.9) 185(29.6) <0.001 
Stroke or TIA 64 (8.3) 66 (10.6) 0.14 
Other Systems    
Type II Diabetes 241(31.1) 254(40.7) 0.0002 
COPD/Asthma 105(13.6) 123(19.7) 0.0021 
Peripheral vascular disease 168 (21.7) 112 (17.9) 0.08 
Anemia 151 (19.5) 199 (21.8) <0.001 
Any alcohol intake  81 (10.5) 157 (25.2) 0.0001 
Heart Failure Characteristics, Investigations and Treatment 
HF hospitalization within past 6 months – 183 (58.1) 207 (61.2)  
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no. (%) 
NYHA 3& 4 – no. (%) 484 (62.5) 333 (53.3) 0.0005 
Quality of Life scores    
Minnesota LWHF – median (Q1, Q3) 43.0 (32.0, 57.0) 38.5 (25.0, 53.0) 0.0028 
KCCQ (Clinical Summary) score – median 
(Q1, Q3) 
56.0 (38.8, 72.9) 60.4 (40.6, 79.7) 0.009 
Peripheral edema 506 (65.4) 409 (65.5) 0.95 
JVD 101 (13.4) 103 (16.9) 0.0683 
Rales 163 (21.1) 129 (21.0) 0.9747 
ECG – no. (%)    
Atrial fibrillation 118 (15.3) 156 (25.0) <0.001 
LVH 167 (21.7) 109 (17.5) 0.052 
Other Investigations    
CXR demonstrating pleural effusion or 
pulmonary. congestion 
196 (25.3) 105 (16.8) <0.001 
NT-proBNP (pg/ml) – median (IQR) 335.0 (126, 981) 517 (203, 1166) 0.0040 
Sodium (mmol/L) - mean (SD) 140.0 (3.1) 139.4 (2.8) 0.21 
Potassium (mmol/L) - mean (SD) 4.3 (0.5) 4.3 (0.4) 0.24 
eGFR (ml/min/1.73m
2
) - mean (SD) 67.2 (23.7) 69.9 (21.4) 0.03 
eGFR <60 ml/min/m
2
 – no. (%) 325 (42.7) 222 (36.0) 0.01 
Drugs and Interventions – no. (%)    
Diuretic 659 (85.1) 541 (86.6) 0.45 
    Loop diuretics 466 (60.2) 434 (69.4) 0.0003 
    Thiazide diuretics 299 (38.6) 178 (28.5) <0.001 
Digitalis 60 (7.8) 70 (11.2) 0.03 
Beta- blocker 538 (69.5) 460 (73.6) 0.09 
Calcium Channel Blocker 343 (44.3) 240 (38.4) 0.03 
Antiarrhythmics 63 (8.1) 47 (7.5) 0.67 
Antiplatelets 437 (56.5) 387 (61.9) 0.03 
Aspirin 413 (53.4) 373 (59.7) 0.02 
Anticoagulants 170 (22.0) 193 (30.9) 0.0002 
Statins 332 (42.9) 345 (55.2) <0.001 
Pacemaker 63 (8.1) 70 (11.2) 0.05 
ICD 4 (0.5) 10 (1.6) 0.04 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), body mass index (BMI), inter quartile range (IQR), 
history of (Hx), chronic obstructive pulmonary disease (COPD). 
New York heart association (NYHA), living with heart failure (LWHF), Kansas City cardiomyopathy questionnaire (KCCQ), jugular 
venous distension (JVD), left ventricular hypertrophy (LVH), bundle branch block (BBB), left ventricular ejection fraction (LVEF), 
chest x-ray (CXR), N terminal -pro brain natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), implantable 
cardioverter defibrillator (ICD). 
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Supplementary Table 3: Clinical outcomes in HFpEF (Echo substudy) 
 Women 
774 (55.3) 
Men 
625 (44.7) 
Adjusted HR 
(Model 1) 
p-value 
Adjusted HR 
(Model 2) 
p-value Total patients with events 
Primary composite 
outcome 
167 188 
0.65 (0.52 – 0.82) 
<0.001 
0.78 (0.60 – 1.02) 
0.067 
     
Heart Failure 
Hospitalization 
131 123 
0.83 (0.64 – 1.08) 
0.171 
1.09 (0.80 – 1.49) 
0.586 
     
Cardiovascular Death 63 89 
0.51 (0.36 – 0.71) 
<0.001 
0.48 (0.32 – 0.73) 
<0.001 
     
Sudden Death 17 34 
0.34 (0.19 – 0.63) 
0.001 
0.24 (0.12 – 0.50) 
<0.001 
     
All-cause Death 109 143 
0.52 (0.40 – 0.68) 
<0.001 
0.55 (0.40 – 0.75) 
<0.001 
     
Hazard Ratios are reported with 95 confidence intervals (CI) within () 
All outcomes have been adjusted for trial, randomized treatment and region at baseline. 
Adjustment Model 1 – age, HR, SBP, DBP, BMI, NYHA classes 3 & 4, LVEF, eGFR, NT-proBNP.  
Adjustment Model 2 – age, HR, SBP, DBP, BMI, NYHA classes 3 & 4, LVEF, eGFR, NT-proBNP, e-wave, left ventricular mass indexed 
to body surface area (BSA) and left atrial volume indexed to BSA. 
All outcomes were tested for competing risks of all-cause and non-cardiovascular death. 
Missing indicator method was used to handle missing eGFR and NT-proBNP values 
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Supplementary Table 4: Clinical outcomes before and after matching by propensity score. 
 Before matching After matching 
No. of events 
Hazard Ratio* 
(women vs. men) 
No. of events 
 Hazard Ratio 
(women vs. men) 
Women 
3373 (57.2) 
Men 
2522 (42.8) 
Women 
830 
Men 
830 
Primary outcome 824 747 
0.84 (0.76 – 0.94) 
0.002 
210 241 
0.83 (0.69 – 0.99) 
0.043 
       
HF hospitalization 580 481 
0.96 (0.84 – 1.09) 
0.505 
144 147 
0.95 (0.76 – 1.20) 
0.693 
       
CV death 415 421 
0.71 (0.61 – 0.82) 
<0.001 
106 138 
0.72 (0.56 – 0.93) 
0.010 
       
All-cause death 615 653 
0.66 (0.59 – 0.74) 
<0.001 
150 214 
0.65 (0.53 – 0.81) 
<0.001 
       
Adjusted for trial, region, randomized treatment, age, HR, SBP, DBP, BMI, NYHA classes III/IV, LVEF, eGFR, NT-proBNP, H/o atrial fibrillation, H/o coronary heart disease, , H/o 
hypertension, H/o stroke, H/o diabetes. 
HR with 95% CI and p-value. 
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Supplementary Figure 1: Kansas City Cardiomyopathy Scores. Y axis represents score out of a possible 
100 (with lower score representing worse quality of life).  
 
 
 
Supplementary Figure 2: Minnesota Living with Heart Failure Scores. Y axis represents score out of a 
possible 100 (with higher score representing worse quality of life).  
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Supplementary Figure 3: Responses to individual questions in the Minnesota Living with Heart Failure questionnaire. Y axis represents response to 
questions (0 – 5) and bars show mean response to each question. 
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Supplementary Figure 4: Standardized differences of covariates between men and women before and after propensity score matching. 
 
